Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The results of all clinical trials and mass immunization programmes carried out over the past few years are extremely encouraging and should be the prelude to systematic immunization. Three vaccines that are immunogenic in infants over 6 weeks old, are now available: HbOC linked to diphtheria toxin, PRP-OMP linked to a meningococcus protein, and PRP-T linked to tetanus toxoid. Their safety has been demonstrated particularly when administration at a very early age before the period of risk. Efficacy has been demonstrated, even in population groups who do not respond well to non-conjugate vaccines. Immunogenicity persists even in unfavourable contexts such as individuals with sickle-cell anaemia or leukosis or a previous history of vaccine failure. The duration of immunity amply covers the period of risk and probably a longer because of the booster effect of natural infections. The possibility of combining Hib vaccine with other routine immunizations in infancy will reduce the cost of this additional immunization. Thus it is possible to envisage its integration into immunization programmes in developing countries. Cost/benefit studies show advantages. What is needed now is to achieve high immunization coverage, guaranteeing efficacy of immunization at national level, by ensuring that health personnel as well as families are fully informed about the seriousness of Hib infections and the good tolerance and efficacy of the conjugate vaccines.
 ...
PMID:[Control of Haemophilus influenzae infections]. 792 93